|
1
|
Stamenkovic I: Extracellular matrix
remodelling: The role of matrix metalloproteinases. J Pathol.
200:448–464. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Van den Steen PE, Dubois B, Nelissen I,
Rudd PM, Dwek RA and Opdenakker G: Biochemistry and molecular
biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit
Rev Biochem Mol Biol. 37:375–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moss Shuman LA, Jensen-Taubman S and
Stetler-Stevenson WG: Matrix metalloproteinases: Changing roles in
tumor progression and metastasis. Am J Pathol. 181:1895–1899. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schaefer L and Iozzo RV: Biological
functions of the small leucine-rich proteoglycans: From genetics to
signal transduction. J Biol Chem. 283:21305–21309. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bi XL and Yang W: Biological functions of
decorin in cancer. Chin J Cancer. 32:266–269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goldoni S, Humphries A, Nyström A, Sattar
S, Owens RT, McQuillan DJ, Ireton K and Iozzo RV: Decorin is a
novel antagonistic ligand of the Met receptor. J Cell Biol.
185:743–754. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Monfort J, Tardif G, Reboul P, Mineau F,
Roughley P, Pelletier JP and Martel-Pelletier J: Degradation of
small leucine-rich repeat proteoglycans by matrix
metalloprotease-13: Identification of a new biglycan cleavage site.
Arthritis Res Ther. 8:R262006. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Imai K, Hiramatsu A, Fukushima D,
Pierschbacher MD and Okada Y: Degradation of decorin by matrix
metalloproteinases: Identification of the cleavage sites, kinetic
analyses and transforming growth factor-beta1 release. Biochem J.
322:809–814. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heathfield TF, Onnerfjord P, Dahlberg L
and Heinegård D: Cleavage of fibromodulin in cartilage explants
involves removal of the N-terminal tyrosine sulfate-rich region by
proteolysis at a site that is sensitive to matrix
metalloproteinase-13. J Biol Chem. 279:6286–6295. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Aoki T, Mori Y, Ahmad M, Miyamori H,
Takino T and Sato H: Cleavage of lumican by membrane-type matrix
metalloproteinase-1 abrogates this proteoglycan-mediated
suppression of tumor cell colony formation in soft agar. Cancer
Res. 64:7058–7064. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shirabe K, Shimada M, Kajiyama K, Hasegawa
H, Gion T, Ikeda Y, Takenaka K and Sugimachi K: Expression of
matrix metalloproteinase-9 in surgically resected intrahepatic
cholangiocarcinoma. Surgery. 126:842–846. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carmeliet P: Mechanisms of angiogenesis
and arteriogenesis. Nat Med. 6:389–395. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liotta LA, Tryggvason K, Garbisa S, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giannelli G, Falk-Marzillier J, Schiraldi
O, Stetler-Stevenson WG and Quaranta V: Induction of cell migration
by matrix metalloprotease-2 cleavage of laminin-5. Science.
277:225–228. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN,
Huang SC and Hsu SM: Increased expression and activation of
gelatinolytic matrix metalloproteinases is associated with the
progression and recurrence of human cervical cancer. Cancer Res.
63:6537–6542. 2003.PubMed/NCBI
|
|
17
|
Wang PH, Ko JL, Tsai HT, Yang SF, Han CP,
Lin LY and Chen GD: Clinical significance of matrix
metalloproteinase-2 in cancer of uterine cervix: A semiquantitative
study of immunoreactivities using tissue array. Gynecol Oncol.
108:533–542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gaiotto MA, Focchi J, Ribalta JL, Stavale
JN, Baracat EC, Lima GR and da Silva Guerreiro ID: Comparative
study of MMP-2 (matrix metalloproteinase 2) immune expression in
normal uterine cervix, intraepithelial neoplasias and squamous
cells cervical carcinoma. Am J Obstet Gynecol. 190:1278–1282. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Argüello-Ramírez J, Pérez-Cárdenas E,
Delgado-Chávez R, Solorza-Luna G, Villa-Treviño S and
Arenas-Huertero F: Matrix metalloproteinases-2, −a3 and −9 secreted
by explants of benign and malignant lesions of the uterine cervix.
Int J Gynecol Cancer. 14:333–340. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sato T, Sakai T, Noguchi Y, Takita M,
Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion
of human uterine cervical carcinoma cells by augmenting the
expression and activation of stromal matrix metalloproteinases.
Gynecol Oncol. 92:47–56. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ahmed N, Riley C, Oliva K, Barker G, Quinn
MA and Rice GE: Expression and localization of alphavbeta6 integrin
in extraplacental fetal membranes: Possible role in human
parturition. Mol Hum Reprod. 10:173–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang SF, Wang PH, Lin LY, Ko JL, Chen GD,
Yang JS, Lee HS and Hsieh YS: A significant elevation of plasma
level of matrix metalloproteinase-9 in patients with high-grade
intraepithelial neoplasia and early squamous cell carcinoma of the
uterine cervix. Reprod Sci. 14:710–718. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baltazar-Rodriguez LM, Anaya-Ventura A,
Andrade-Soto M, Monrroy-Guizar EA, Bautista-Lam JR,
Jonguitud-Olguin G, Cepeda-Lopez FR, Centeno-Aguilar VA,
Gonzalez-Hernandez NA, Soriano-Hernández AD, et al: Polymorphism in
the matrix metalloproteinase-2 gene promoter is associated with
cervical neoplasm risk in Mexican women. Biochem Genet. 46:137–144.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rauvala M, Aglund K, Puistola U,
Turpeenniemi-Hujanen T, Horvath G, Willén R and Stendahl U: Matrix
metalloproteinases-2 and −9 in cervical cancer: Different roles in
tumor progression. Int J Gynecol Cancer. 16:1297–1302. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nasr M, Ayyad SB, El-Lamie IK and Mikhail
MY: Expression of matrix metalloproteinase-2 in preinvasive and
invasive carcinoma of the uterine cervix. Eur J Gynaecol Oncol.
26:199–202. 2005.PubMed/NCBI
|
|
26
|
Yoshida H, Sumi T, Hyun Y, Nakagawa E,
Hattori K, Yasui T, Morimura M, Honda K, Nakatani T and Ishiko O:
Expression of survivin and matrix metalloproteinases in
adenocarcinoma and squamous cell carcinoma of the uterine cervix.
Oncol Rep. 10:45–49. 2003.PubMed/NCBI
|
|
27
|
Talvensaari-Mattila A,
Turpeenniemi-Hujanen T and Puistola U: Matrix metalloproteinase 9
and relapse in patients with early stage squamous cervical
carcinoma. Int J Gynaecol Obstet. 91:75–76. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Talvensaari-Mattila A and
Turpeenniemi-Hujanen T: Matrix metalloproteinase 9 in the uterine
cervix during tumor progression. Int J Gynaecol Obstet. 92:83–84.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tellier E, Nègre-Salvayre A, Bocquet B,
Itohara S, Hannun YA, Salvayre R and Augé N: Role for furin in
tumor necrosis factor alpha-induced activation of the matrix
metalloproteinase/sphingolipid mitogenic pathway. Mol Cell Biol.
27:2997–3007. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Corsi A, Xu T, Chen XD, Boyde A, Liang J,
Mankani M, Sommer B, Iozzo RV, Eichstetter I, Robey PG, et al:
Phenotypic effects of biglycan deficiency are linked to collagen
fibril abnormalities, are synergized by decorin deficiency, and
mimic Ehlers-Danlos-like changes in bone and other connective
tissues. J Bone Miner Res. 17:1180–1189. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iozzo RV: The biology of the small
leucine-rich proteoglycans. Functional network of interactive
proteins. J Biol Chem. 274:18843–18846. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Keene DR, Antonio San JD, Mayne R,
McQuillan DJ, Sarris G, Santoro SA and Iozzo RV: Decorin binds near
the C terminus of type I collagen. J Biol Chem. 275:21801–21804.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bidanset DJ, Guidry C, Rosenberg LC, Choi
HU, Timpl R and Hook M: Binding of the proteoglycan decorin to
collagen type VI. J Biol Chem. 267:5250–5256. 1992.PubMed/NCBI
|
|
34
|
Schonherr E, Hausser H, Beavan L and
Kresse H: Decorin-type I collagen interaction. Presence of separate
core protein-binding domains. J Biol Chem. 270:8877–8883. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kinsella MG, Bressler SL and Wight TN: The
regulated synthesis of versican, decorin, and biglycan:
Extracellular matrix proteoglycans that influence cellular
phenotype. Crit Rev Eukaryot Gene Expr. 14:203–234. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nareyeck G, Seidler DG, Troyer D,
Rauterberg J, Kresse H and Schönherr E: Differential interactions
of decorin and decorin mutants with type I and type VI collagens.
Eur J Biochem. 271:3389–3398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Danielson KG, Baribault H, Holmes DF,
Graham H, Kadler KE and Iozzo RV: Targeted disruption of decorin
leads to abnormal collagen fibril morphology and skin fragility. J
Cell Biol. 136:729–743. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Järveläinen H, Puolakkainen P, Pakkanen S,
Brown EL, Höök M, Iozzo RV, Sage EH and Wight TN: A role for
decorin in cutaneous wound healing and angiogenesis. Wound Repair
Regen. 14:443–452. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Iozzo RV, Chakrani F, Perrotti D,
McQuillan DJ, Skorski T, Calabretta B and Eichstetter I:
Cooperative action of germ-line mutations in decorin and p53
accelerates lymphoma tumorigenesis. Proc Natl Acad Sci USA.
96:3092–3097. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Csordás G, Santra M, Reed CC, Eichstetter
I, McQuillan DJ, Gross D, Nugent MA, Hajnoczky G and Iozzo RV:
Sustained down-regulation of the epidermal growth factor receptor
by decorin. A mechanism for controlling tumor growth in vivo. J
Biol Chem. 275:32879–32887. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhu JX, Goldoni S, Bix G, Owens RT,
McQuillan DJ, Reed CC and Iozzo RV: Decorin evokes protracted
internalization and degradation of the epidermal growth factor
receptor via caveolar endocytosis. J Biol Chem. 280:32468–32479.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Seidler DG, Faiyaz-Ul-Haque M, Hansen U,
Yip GW, Zaidi SH, Teebi AS, Kiesel L and Götte M: Defective
glycosylation of decorin and biglycan, altered collagen structure,
and abnormal phenotype of the skin fibroblasts of an Ehlers-Danlos
syndrome patient carrying the novel Arg270Cys substitution in
galactosyltransferase I (beta4GalT-7). J Mol Med (Berl).
84:583–594. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Seidler DG, Goldoni S, Agnew C, Cardi C,
Thakur ML, Owens RT, McQuillan DJ and Iozzo RV: Decorin protein
core inhibits in vivo cancer growth and metabolism by hindering
epidermal growth factor receptor function and triggering apoptosis
via caspase-3 activation. J Biol Chem. 281:26408–26418. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Koninger J, Giese T, di Mola FF, Wente MN,
Esposito I, Bachem MG, Giese NA, Büchler MW and Friess H:
Pancreatic tumor cells influence the composition of the
extracellular matrix. Biochem Biophys Res Commun. 322:943–949.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Skandalis SS, Kletsas D, Kyriakopoulou D,
Stavropoulos M and Theocharis DA: The greatly increased amounts of
accumulated versican and decorin with specific post-translational
modifications may be closely associated with the malignant
phenotype of pancreatic cancer. Biochim Biophys Acta.
1760:1217–1225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Border WA, Noble NA, Yamamoto T, Harper
JR, Yamaguchi YU, Pierschbacher MD and Ruoslahti E: Natural
inhibitor of transforming growth factor-beta protects against
scarring in experimental kidney disease. Nature. 360:361–364. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hildebrand A, Romaris M, Rasmussen LM,
Heinegård D, Twardzik DR, Border WA and Ruoslahti E: Interaction of
the small interstitial proteoglycans biglycan, decorin and
fibromodulin with transforming growth factor beta. Biochem J.
302:527–534. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Grant DS, Yenisey C, Rose RW, Tootell M,
Santra M and Iozzo RV: Decorin suppresses tumor cell-mediated
angiogenesis. Oncogene. 21:4765–4777. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nash MA, Loercher AE and Freedman RS: In
vitro growth inhibition of ovarian cancer cells by decorin:
Synergism of action between decorin and carboplatin. Cancer Res.
59:6192–6196. 1999.PubMed/NCBI
|
|
50
|
Reed CC, Waterhouse A, Kirby S, Kay P,
Owens RT, McQuillan DJ and Iozzo RV: Decorin prevents metastatic
spreading of breast cancer. Oncogene. 24:1104–1110. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Santra M, Skorski T, Calabretta B, Lattime
EC and Iozzo RV: De novo decorin gene expression suppresses the
malignant phenotype in human colon cancer cells. Proc Natl Acad Sci
USA. 92:7016–7020. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Köninger J, Giese NA, di Mola FF, Berberat
P, Giese T, Esposito I, Bachem MG, Buchler MW and Friess H:
Overexpressed decorin in pancreatic cancer: Potential tumor growth
inhibition and attenuation of chemotherapeutic action. Clin Cancer
Res. 10:4776–4783. 2004. View Article : Google Scholar : PubMed/NCBI
|
